Pemphigus: A treatment update

American Journal of Clinical Dermatology

Volumn 9, Issue 3, 2008, Pages 147-154

  Jessop, Sue ^a   Khumalo, Nonhlanhla P ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Azathioprine, therapeutic use; Calcineurin inhibitors, therapeutic use; Ciclosporin, therapeutic use; Corticosteroids, therapeutic use; Cyclophosphamide, therapeutic use; Epidermal growth factor, therapeutic use; Mycophenolate mofetil, therapeutic use

Indexed keywords

AZATHIOPRINE; BETAMETHASONE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PILOCARPINE; PREDNISOLONE; PREDNISONE; SULFADIAZINE SILVER;

ANAPHYLAXIS; ASEPTIC MENINGITIS; BACKACHE; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE SEVERITY; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; FEVER; FLUSHING; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPOTENSION; INFECTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOW DRUG DOSE; MOOD CHANGE; MOOD DISORDER; MYOPATHY; NAUSEA; OUTCOME ASSESSMENT; PATHOGENESIS; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; REVIEW; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; BIOLOGICAL PRODUCTS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEMPHIGUS;

EID: 42449138686     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200809030-00002     Document Type: Review

References (59)

1. Scully C, Challacombe SJ. Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. Crit Rev Oral Biol Med 2002; 13: 397-408
2. Ugajin T, Yahara H, Moriyama Y, et al. Two siblings with neonatal pemphigus vulgaris associated with mild maternal disease. Br J Dermatol 2007; 157 (1): 192-4
3. Campo-Voegeli A. Neonatal pemphigus vulgaris with extensive mucocutaneous lesions from a mother with oral pemphigus vulgaris. Br J Dermatol 2002; 147: 801-5
4. Ribeiro AM, Alvarez RR, Friedman H, et al. The profile of fogo selvagem (endemic pemphigus foliaceus) at the University Hospital of Brasilia-Brazil: epidemiological and clinical considerations. Int J Dermatol 2005 Apr; 44 (4): 293-8
5. Esmaili N, Chams-Davatchi C, Valikhani M, et al. Pemphigus vulgaris in Iran: a clinical study of 140 cases. Int J Dermatol 2007; 46: 1166-70
6. Mahoney M, Wang Z, Rothenberger K, et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999; 103: 461-8
7. Martin LK, Werth VP, Agero AL, et al. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2006; (4): CD006263
8. Chams-Davatchi C, Valikhani M, Daneshpazhooh M, et al. Pemphigus: analysis of 1209 cases. J Dermatol 2005 Jun; 44 (6): 470-6
9. Herbst A, Bystryn JC. Patterns of remission in pemphigus vulgaris. J Am Acad Dermatol 2000; 42 (3): 422-7
10. Mourellou O. The treatment of pemphigus vulgaris: experience with 48 patients seen over an 11-year period. Br J Dermatol 1995; 133: 83-7
11. Rosenberg F. Pemphigus: a 20-year review of 107 patients treated with corticosteroids. Arch Dermatol 1976; 112: 962-70
12. Carson PJ, Hameed A, Ahmed AR. Influence of treatment on the clinical course of pemphigus vulgaris. J Am Acad Dermatol 1996; 34 (4): 645-52
13. Amagai M, Karpati S, Prussick R, et al. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992; 90 (3): 919-26
14. Amagai M, Ahmed AR, Kitajima Y, et al. Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just "witnesses of disease"? Exp Dermatol 2006 Oct; 15 (10): 815-31
15. Nguyen VT, Arredondo J, Chernyavsky AI, et al. Pemphigus vulgaris acantholysis ameliorated by cholinergic agents. Arch Dermatol 2004; 140: 327-34
16. Arredondo J, Chernyavsky AI, Karaouni A, et al. Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in pemphigus. Am J Pathol 2005; 167: 1531-44
17. Grando SA, Dahl MV. Nicotine and pemphigus [letter]. Arch Dermatol 2000; 136: 1269
18. Amagai M, Tsunoda K, Zillikens D, et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999; 40: 167-70
19. Kumar B, Arora S, Kumaran MS, et al. Study of desmoglein 1 and 3 antibody levels in relation to disease severity in Indian patients with pemphigus. J Dermatol Venereol Leprol 2006; 72: 203-6
20. Pfutze M, Niedermeier A, Hertl M, et al. Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus. Eur J Dermatol 2007 Jan-Feb; 17 (1): 4-11
21. Engineer L, Bhol KC, Ahmed AR. Analysis of current data on the use of intravenous immunoglobulins in the management of pemphigus vulgaris. J Am Acad Dermatol 2000; 43 (6): 1049-57
22. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149 (5): 926-37
23. Ratnam KV, Phay KL, Tan CK. Pemphigus therapy with oral prednisolone regimens: a 5-year study. Int J Dermatol 1990 Jun; 29 (5): 363-7
24. Femiano F, Gombos F, Scully C. Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol 2002 Jul; 16 (4): 353-6
25. Mentink LF, Mackenzie MW, Toth GG, et al. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol 2006 May; 142 (5): 570-6
26. Chryssomallis F. Steroid-pulse therapy in pemphigus vulgaris long term follow-up. Int J Dermatol 1995; 34: 438-42
27. Rose E, Wever S, Zilliken D, et al. Intravenous dexamethasone- cyclophosphamide pulse therapy in comparison with oral methylprednisolone- azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study. J Dtsch Dermatol Ges 2005 Mar; 3 (3): 200-6
28. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006 Nov; 142 (11): 1447-54
29. Ioannides D. Ineffectiveness of cyclosporin as an adjuvant to corticosteroids in the treatment of pemphigus. Arch Dermatol 2000; 136: 868-72
30. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57: 622-8
31. Guillaume J. Controlled study of plasma exchange in pemphigus. Arch Dermatol 1988; 124: 1659-63
32. Iraji F, Yoosefi A. Healing effect of pilocarpine gel 4% on skin lesions of pemphigus vulgaris. Int J Dermatol 2006 Jun; 45 (6): 743-6
33. Tabrizi MN, Chams-Davatchi C, Esmaeeli N, et al. Accelerating effects of epidermal growth factor on skin lesions of pemphigus vulgaris: a double-blind, randomized, controlled trial. J Eur Acad Dermatol Venereol 2007 Jan; 21 (1): 79-84
34. Olszewska M, Kolacinska-Strasz Z, Sulej J, et al. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol 2007; 8 (2): 85-92
35. Lüftl M, Stauber A, Mainka A, et al. Successful removal of pathogenic autoantibodies in pemphigus by immunoadsorption with a tryptophan-linked polyvinylalcohol adsorber. Br J Dermatol 2003; 149 (3): 598-605
36. Eming R, Rech J, Barth S, et al. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption. Dermatology 2006; 212 (2): 177-87
37. Schmidt E, Klinker E, Opitz A, et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003; 148: 1222-9
38. Shimanovich I, Herzog S, Schmidt E, et al. Improved protocol for treatment of pemphigus vulgaris with protein A immunoadsorption. Clin Exp Dermatol 2006; 31: 768-74
39. Termeer CC, Technau K, Augustin M, et al. Topical tacrolimus (Protopic) for the treatment of a localized pemphigus foliaceus. J Eur Acad Dermatol Venereol 2004 Sep; 18 (5): 636-7
40. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003 Aug; 139 (8): 1051-9
41. Lin MH, Hsu CK, Lee JY. Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser. Arch Dermatol 2005 Jun; 141 (6): 680-2
42. Pardo J, Mercader P, Mahiques L, et al. Infliximab in the management of severe pemphigus vulgaris. Br J Dermatol 2005 Jul; 153 (1): 222-3
43. Arin M. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005; 153: 620-5
44. Cooper H. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 2003; 28: 366-8
45. Dupuy A. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol 2004; 140: 91-6
46. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355 (17): 1772-9
47. Goh MS, McCormack C, Dinh HV, et al. Rituximab in the adjuvant treatment pemphigus vulgaris: a prospective open-label pilot study in five patients. Br Dermatol 2007; 156 (5): 990-6
48. Herrmann G, Hunzelmann N, Engert A. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol 2003; 148 (3): 602-3
49. Goebeler M, Herzog S, Bröcker E-B, et al. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003; 149 (4): 899-901
50. Kong HH, Prose NS, Ware RE, et al. Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol 2005 Sep-Oct; 22 (5): 461-4
51. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004; 51 (5): 817-9
52. Schmidt E. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005; 153 (2): 449-51
53. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-52
54. Schmidt E, Seitz CS, Benoit S, et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352-6
55. Heaphy MR, Albrecht J, Werth VP. Dapsone as a glucocorticoid-sparing agent maintenance-phase pemphigus vulgaris. Arch Dermatol 2005 Jun; 141 (6): 699-702
56. Vanikar AV, Modi PR, Patel RD, et al. Hematopoietic stem cell transplantation autoimmune diseases: the Ahmedabad experience. Transplant Proc 2007; 39 (3): 703-8
57. Angelini G, Bonamonte D, Lucchese A, et al. Preliminary data on pemphigus vulgaris treatment by a proteomics-defined peptide: a case report. J Transl Med 2006; 4: 43
58. Anhalt G, Werth V, Strober B, et al. An open-label phase I clinical study to assess the safety of PI-0824 in patients with pemphigus vulgaris [online]. Available from URL: http://www.Nature.com/jid/journal/v125/n5/pdf/5603636a.pdf [Accessed 2007 Sep 18]
59. Fardet L, Flahault A, Kettaneh A, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007; 157 (1): 142-8